Cardiol Therapeutics (CRDL) Competitors

$1.36 +0.01 (+0.37%)

Closing price 03:59 PM Eastern

Extended Trading

$1.36 0.00 (0.00%)

As of 04:04 PM Eastern

CRDL vs. CRMD, OCGN, DNA, ZVRA, and STRO

Should you buy Cardiol Therapeutics stock or one of its competitors? MarketBeat compares Cardiol Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardiol Therapeutics include CorMedix (CRMD), Ocugen (OCGN), Ginkgo Bioworks (DNA), Zevra Therapeutics (ZVRA), and Sutro Biopharma (STRO). These companies are all part of the "pharmaceutical products" industry.

How does Cardiol Therapeutics compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CorMedix currently has a consensus price target of $15.00, indicating a potential upside of 84.39%. Cardiol Therapeutics has a consensus price target of $8.50, indicating a potential upside of 526.84%. Given Cardiol Therapeutics' higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cardiol Therapeutics had 1 more articles in the media than CorMedix. MarketBeat recorded 10 mentions for Cardiol Therapeutics and 9 mentions for CorMedix. CorMedix's average media sentiment score of 0.63 beat Cardiol Therapeutics' score of -0.02 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CorMedix has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

CorMedix has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	2.05	$163.05M	$2.00	4.07
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

CorMedix has a net margin of 52.31% compared to Cardiol Therapeutics' net margin of 0.00%. CorMedix's return on equity of 52.30% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	52.31%	52.30%	29.46%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Summary

CorMedix beats Cardiol Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Ocugen?

Cardiol Therapeutics (NASDAQ:CRDL) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

12.5% of Cardiol Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 5.3% of Cardiol Therapeutics shares are held by company insiders. Comparatively, 4.0% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cardiol Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.3, suggesting that its stock price is 130% more volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to Ocugen's net margin of -1,192.18%. Cardiol Therapeutics' return on equity of -229.43% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Ocugen	-1,192.18%	-127,987.80%	-135.48%

Cardiol Therapeutics has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Ocugen	$4.47M	110.31	-$67.85M	-$0.24	N/A

In the previous week, Ocugen had 20 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 30 mentions for Ocugen and 10 mentions for Cardiol Therapeutics. Ocugen's average media sentiment score of 0.58 beat Cardiol Therapeutics' score of -0.02 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	7 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cardiol Therapeutics presently has a consensus target price of $8.50, suggesting a potential upside of 526.84%. Ocugen has a consensus target price of $9.75, suggesting a potential upside of 570.10%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Ocugen beats Cardiol Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

78.6% of Ginkgo Bioworks shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 12.7% of Ginkgo Bioworks shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cardiol Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Cardiol Therapeutics has lower revenue, but higher earnings than Ginkgo Bioworks. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	2.89	-$312.76M	-$5.36	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

Ginkgo Bioworks presently has a consensus price target of $8.50, suggesting a potential upside of 6.99%. Cardiol Therapeutics has a consensus price target of $8.50, suggesting a potential upside of 526.84%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Ginkgo Bioworks has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

In the previous week, Ginkgo Bioworks had 2 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 12 mentions for Ginkgo Bioworks and 10 mentions for Cardiol Therapeutics. Cardiol Therapeutics' average media sentiment score of -0.02 beat Ginkgo Bioworks' score of -0.19 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ginkgo Bioworks beats Cardiol Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Zevra Therapeutics had 12 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 22 mentions for Zevra Therapeutics and 10 mentions for Cardiol Therapeutics. Zevra Therapeutics' average media sentiment score of 0.46 beat Cardiol Therapeutics' score of -0.02 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	6.54	$83.23M	$1.99	5.92
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Zevra Therapeutics currently has a consensus target price of $23.33, suggesting a potential upside of 97.99%. Cardiol Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 526.84%. Given Cardiol Therapeutics' higher possible upside, analysts clearly believe Cardiol Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Zevra Therapeutics has a net margin of 101.58% compared to Cardiol Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Summary

Zevra Therapeutics beats Cardiol Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Cardiol Therapeutics compare to Sutro Biopharma?

Cardiol Therapeutics (NASDAQ:CRDL) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Cardiol Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A
Sutro Biopharma	$102.48M	6.32	-$191.09M	-$26.10	N/A

Cardiol Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 526.84%. Sutro Biopharma has a consensus price target of $40.78, suggesting a potential upside of 4.23%. Given Cardiol Therapeutics' higher probable upside, equities research analysts plainly believe Cardiol Therapeutics is more favorable than Sutro Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sutro Biopharma	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Cardiol Therapeutics has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cardiol Therapeutics has a net margin of 0.00% compared to Sutro Biopharma's net margin of -186.45%. Sutro Biopharma's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-229.43%	-165.60%
Sutro Biopharma	-186.45%	N/A	-79.02%

In the previous week, Cardiol Therapeutics had 9 more articles in the media than Sutro Biopharma. MarketBeat recorded 10 mentions for Cardiol Therapeutics and 1 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 0.58 beat Cardiol Therapeutics' score of -0.02 indicating that Sutro Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardiol Therapeutics	Neutral
Sutro Biopharma	Positive

Summary

Sutro Biopharma beats Cardiol Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Cardiol Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRDL vs. The Competition

Export

Metric	Cardiol Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$151.52M	$3.04B	$6.29B	$12.46B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	-4.84	18.81	20.85	25.56
Price / Sales	N/A	279.58	543.57	72.25
Price / Cash	N/A	56.53	42.94	55.34
Price / Book	8.48	4.36	9.87	6.72
Net Income	-$24.20M	$72.19M	$3.55B	$333.62M
7 Day Performance	4.31%	-0.61%	-0.23%	0.35%
1 Month Performance	-3.14%	0.34%	1.47%	4.00%
1 Year Performance	22.16%	46.24%	41.05%	36.32%

Cardiol Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRDL Cardiol Therapeutics	2.2519 of 5 stars	$1.37 +0.4%	$8.50 +522.7%	+18.8%	$152.63M	N/A	N/A	20	News Coverage Earnings Report Analyst Revision
CRMD CorMedix	3.0098 of 5 stars	$7.90 +1.4%	$15.00 +89.9%	-35.5%	$611.07M	$311.71M	3.95	30	News Coverage Earnings Report Options Volume Gap Up
OCGN Ocugen	1.7579 of 5 stars	$1.85 +2.8%	$9.75 +427.0%	+109.3%	$609.33M	$4.41M	N/A	80	Trending News Analyst Revision
DNA Ginkgo Bioworks	0.949 of 5 stars	$9.95 +2.5%	$8.50 -14.5%	+5.7%	$600.67M	$170.15M	N/A	640	High Trading Volume
ZVRA Zevra Therapeutics	4.0295 of 5 stars	$10.05 -0.2%	$23.00 +128.9%	+41.3%	$595.29M	$106.47M	7.56	20	Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRDL) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. CRMD, OCGN, DNA, ZVRA, and STRO

How does Cardiol Therapeutics compare to CorMedix?

Summary

How does Cardiol Therapeutics compare to Ocugen?

Summary

How does Cardiol Therapeutics compare to Ginkgo Bioworks?

Summary

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Summary

How does Cardiol Therapeutics compare to Sutro Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardiol Therapeutics (CRDL) Competitors

CRDL vs. CRMD, OCGN, DNA, ZVRA, and STRO

How does Cardiol Therapeutics compare to CorMedix?

Do institutionals and insiders believe in CRMD or CRDL?

Do analysts rate CRMD or CRDL?

Does the media favor CRMD or CRDL?

Which has more risk & volatility, CRMD or CRDL?

Which has stronger valuation and earnings, CRMD or CRDL?

Is CRMD or CRDL more profitable?

Summary

How does Cardiol Therapeutics compare to Ocugen?

Do insiders & institutionals have more ownership in CRDL or OCGN?

Which has more volatility and risk, CRDL or OCGN?

Is CRDL or OCGN more profitable?

Which has preferable earnings and valuation, CRDL or OCGN?

Does the media favor CRDL or OCGN?

Do analysts rate CRDL or OCGN?

Summary

How does Cardiol Therapeutics compare to Ginkgo Bioworks?

Do insiders & institutionals have more ownership in DNA or CRDL?

Is DNA or CRDL more profitable?

Which has stronger earnings & valuation, DNA or CRDL?

Do analysts prefer DNA or CRDL?

Which has more volatility & risk, DNA or CRDL?

Does the media refer more to DNA or CRDL?

Summary

How does Cardiol Therapeutics compare to Zevra Therapeutics?

Does the media refer more to ZVRA or CRDL?

Which has more risk and volatility, ZVRA or CRDL?

Which has higher valuation and earnings, ZVRA or CRDL?

Do insiders and institutionals have more ownership in ZVRA or CRDL?

Do analysts recommend ZVRA or CRDL?

Is ZVRA or CRDL more profitable?

Summary

How does Cardiol Therapeutics compare to Sutro Biopharma?

Which has higher valuation and earnings, CRDL or STRO?

Do analysts rate CRDL or STRO?

Which has more volatility & risk, CRDL or STRO?

Do insiders & institutionals hold more shares of CRDL or STRO?

Is CRDL or STRO more profitable?

Does the media refer more to CRDL or STRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRDL vs. The Competition

Cardiol Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools